A 24-Week Study of the Efficacy and Safety of BLU-5937 in Adults With Refractory Chronic Cough (CALM-2)

Authors
Category Primary study
Registry of Trialsclinicaltrials.gov
Year 2023
This is a randomized, double-blind, placebo-controlled, parallel-arm, Phase 3 study of BLU-5937 in participants with Refractory Chronic Cough (RCC).
Epistemonikos ID: 8b39bc8f33c2a99a19a43f98672826fc67c0c7b4
First added on: May 14, 2024